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PURPOSE. To investigate the precipitation process of a mixture
of vancomycin and ceftazidime by equilibrium dialysis and
determine its subsequent effect on the level of free antibiotics
for treatment of endophthalmitis.
METHODS. Concentrations of vancomycin and ceftazidime in an
equilibrium dialysis chamber were measured during the equi-
librium process by high-performance liquid chromatography.
Normal saline (NS), balanced salt solution (BSS), and vitreous
were used separately as the medium of dialysis.
RESULTS. Precipitation of ceftazidime occurred at 37°C but not
at room temperature and did not affect the pH of the medium.
It formed precipitate on its own or when mixed with vanco-
mycin in all the three media of NS, BSS, and vitreous. More
precipitation was formed if ceftazidime was initially prepared
in BSS than in NS. After 168 hours in the dialysis chambers,
ceftazidime prepared in NS precipitated to 54% of that in
vitreous, compared with 88% if prepared in BSS. At 48 hours,
ceftazidime prepared in NS decreased from an initial concen-
tration of 137.5 to 73.4 g/mL in vitreous medium and to 6.3
g/mL if prepared in BSS. Precipitation of vancomycin was
negligible.
CONCLUSIONS. Based on this in vitro investigation, ceftazidime
precipitates in vitreous at body temperature, regardless of the
presence of vancomycin. NS is preferred to BSS as a prepara-
tion medium for antibiotics for intravitreal injection, because
the extent of ceftazidime precipitation is less. However, due to
precipitation, the concentration of free ceftazidime in vitreous
may not be sufficiently high for antibacterial activity against
most common organisms. (Invest Ophthalmol Vis Sci. 2002;43:
1182–1188)
Infective endophthalmitis is a potentially blinding conditionand remains a serious postoperative complication of such
frequently performed eye surgeries as cataract extraction.1–3
The infection can be due to a wide variety of bacterial strains,
although Staphylococcus species are the cause in more than
50% of the cases. Intravitreal vancomycin is considered to be
the treatment of choice for Gram-positive organisms. It is
nontoxic in the recommended clinical dosage and is active
against almost all Gram-positive organisms, including methicil-
lin-resistant Staphylococcus aureus.4–6 To combat infection by
Gram-negative organisms, a combination of intravitreal vanco-
mycin and aminoglycosides, such as amikacin or gentamicin,
have been used commonly.5,7,8 However, there has been in-
creasing reported occurrence of macular infarction after intra-
vitreal injection of aminoglycosides.7 Substitution with other
antibiotics has therefore been advocated.8–10 Ceftazidime,9 a
cephalosporin with broad-spectrum antibacterial action, is
now frequently administered together with vancomycin.11 Its
antibacterial action is as effective as that of the aminoglyco-
sides and it poses low risk for macular infarction.6,12 Physico-
chemical incompatibility of vancomycin and ceftazidime is
known to lead to precipitation, but this combination has been
a widely accepted treatment regimen for years, without clinical
drawback.10,13 It has been thought that precipitation can be
avoided by using separate syringes to inject the two antibiot-
ics.8
However, a recent report described the formation of whit-
ish microprecipitates after the two drugs were injected into
the eye intravitreally through separate syringes.14 The precip-
itates were presumed to be formed by an amalgamation of the
compounds. So far, there is no evidence as to whether the
precipitation disrupts the therapeutic effects of the antibiotics,
nor is it clear whether it is a consistent event. In view of the
uncertainty of the nature of the precipitate and its possible
effects on the bioavailability of the antibiotics, we investigate
the precipitation process of a mixture of vancomycin and
ceftazidime by equilibrium dialysis.
METHODS
All experiments were conducted in duplicate, and the mean values
taken as results. Vitreous was obtained from cadaveric donor eyes. The
standard intravitreal dosage of vancomycin (Abbott, Chicago, IL) and
ceftazidime (Fortum; Glaxo Wellcome, Greenford, UK) for treatment
of infective bacterial endophthalmitis was 1 and 2.2 mg respectively,
prepared in 0.1 mL of 0.9% normal saline (NS; Otsuka, Guangdong,
China) or balanced salt solution with glutathione (BSS Plus; Alcon, Fort
Worth, TX), herein referred to as BSS.5,6 The vitreous volume of an
adult emmetropic human eye is approximately 4 mL, giving a respec-
tive empiric concentration of 0.25 and 0.55 mg/mL for vancomycin
and ceftazidime, respectively, when injected into the vitreous. The
actual concentrations would be different, depending on the extent of
precipitation and the actual vitreous volume.
Assay of Antibiotics
Ceftazidime was assayed by high-performance liquid chromatography
(HPLC)15 and vancomycin by a fluorescence polarization immunoassay
(TDx; Abbott Laboratories, Diagnostics Division, Abbott Park, IL).
From the Departments of 1Ophthalmology and Visual Sciences
and 2Microbiology, The Chinese University of Hong Kong, Hong Kong,
China.
Supported by a block grant to the Chinese University of Hong
Kong.
Submitted for publication July 2, 2001; revised November 8, 2001;
accepted December 4, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked “advertise-
ment” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Chi Pui Pang, Department of Ophthalmol-
ogy and Visual Sciences, The Chinese University of Hong Kong, Hong
Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong;
cppang@cuhk.edu.hk.
Investigative Ophthalmology & Visual Science, April 2002, Vol. 43, No. 4
1182 Copyright © Association for Research in Vision and Ophthalmology
Downloaded from iovs.arvojournals.org on 06/29/2019
Study 1: Visual and pH Test
Standard mixture solutions of 1 mg vancomycin and 2.2 mg ceftazi-
dime in 0.1 mL of 0.9% NS or BSS were mixed separately with 4 mL NS,
BSS, or vitreous for incubation at ambient temperature or at 37°C.
Study 2: Checkerboard Analysis
Mixture samples with various concentrations of ceftazidime and van-
comycin prepared in NS or BSS were incubated at 37°C in microtiter
plates (Table 1) covered with paraffin foil. Aliquots were taken at 24
and 48 hours for assays by HPLC (ceftazidime) and fluorescence po-
larization (vancomycin) to determine the amount of free drugs.
Study 3: Control Experiment of Equilibrium
Dialysis with NS as the Medium
Equilibrium dialysis studies were performed in an equilibrium dialyzer
(Spectrum Medical Industries, Los Angeles, CA) with a half-cell work-
ing volume of 5.0 mL vancomycin (625 g) and ceftazidime (1375 g)
prepared in NS. The mixtures were added to half-cell chamber A,
which was separated from half-cell chamber B by a semipermeable
dialysis membrane (Spectrapor; Medical Industries) with a molecular
weight cutoff at 6000 to 8000. Both chambers were filled with 5 mL
NS. The whole system was incubated at 37°C. Aliquots were taken
from half-cell chamber B at appropriate time intervals up to 168 hours
for antibiotic assays.
Study 4: Control Experiment of Equilibrium
Dialysis with BSS as the Medium
The procedure was the same as that used in study 3, but with BSS as
the preparation medium in both chambers.
Study 5: Equilibrium Dialysis in Vitreous
The same procedure was used as in study 3, but with vitreous as the
medium in both chambers. Because the volume of available vitreous
was small, an equilibrium dialysis apparatus with a half-cell chamber
volume of 1 mL instead of 5 mL was used. Accordingly, 125 g
vancomycin and 275 g ceftazidime were added to maintain the same
concentrations as in previous studies. The antibiotics were prepared in
NS before addition into the chambers. The experiment was repeated
with the antibiotics prepared in BSS.
RESULTS
Study 1: Visual and pH Test
Precipitate was visually detected in NS, BSS, and vitreous after
incubation for 1 day at 37°C but not at ambient temperature.
There was no change in the pH of 7.2 before or after precip-
itation.
Study 2: Checkerboard Analysis
In NS, vancomycin alone showed neither visual precipitation
nor measurable decrease after 24 or 48 hours (Tables 1B–E).
Ceftazidime alone decreased in concentration from 0% to
24.7%, suggesting precipitation (first column, Tables 1D, 1E).
In mixtures of ceftazidime and vancomycin, there were no
changes in vancomycin concentration but a progressive de-
crease in ceftazidime after 48 hours (median, 26.8%; range
12.0%–39.7%; Table 1E), suggesting precipitation of ceftazi-
dime but not vancomycin. The decrease in concentration of
the antibiotics was taken as the extent of precipitation.
In BSS preparation, vancomycin alone precipitated from
10.9% to 34.2% after 48 hours (median, 15.5%; first row, Table
1I). With ceftazidime alone, much more precipitation occurred
in BSS than in NS. After 48 hours, the median decrease was
94.9% (range, 93.7%–95.8%; first column, Table 1I). In mixture,
the extent of precipitation was similar, as if the antibiotics
were on their own (Tables 1H, 1I). In both the NS and BSS
mixtures, varying concentrations of vancomycin apparently
did not influence ceftazidime concentration.
Study 3: Control Experiment of Equilibrium
Dialysis with NS as the Medium
The vancomycin concentration in chamber B rose to approx-
imately 45% of the original concentration in chamber A after
approximately 60 hours and then reached a plateau, showing
no loss to the end of the experiment at 168 hours. For cefta-
zidime, after an initial crossover into chamber B for the first 20
hours, there was a steady decline in concentration to approx-
imately 20% at 168 hours, suggesting precipitation. After 168
hours, the total amount of free vancomycin in chambers A and
B was 591.1 g and of free ceftazidime, 577.0 g, compared
with the respective initial levels of 625 and 1375 g. Accord-
ingly, vancomycin decreased by 5.4% and ceftazidime by
58.0%. The decrease was attributed to precipitation.
Study 4: Control Experiment of Equilibrium
Dialysis with BSS as the Medium
Vancomycin concentration in chamber B increased in the first
60 hours as in study 3. For ceftazidime, after an initial crossover
into chamber B in the first 10 hours, there was a steady
decrease by more than 90% after 120 hours. After 168 hours,
the total amounts of free vancomycin in chambers A and B
were 549.4 g and of free ceftazidime, 244.2 g, compared
with the respective initial levels of 625 and 1375 g. Decreases
of 12.1% vancomycin and 82.0% ceftazidime occurred—again,
attributable to precipitation.
Study 5: Equilibrium Dialysis in Vitreous
First, the antibiotics were prepared in NS before addition into
chamber A with vitreous as the medium in cell chambers A and
B. The vancomycin concentration in chamber B increased to
slightly more than 50% of the original concentration in cham-
ber A after approximately 70 hours. For ceftazidime, after an
initial crossover into chamber B in the first 10 hours, there was
a decrease in concentration by more than 80% after 120 hours
(Fig. 1A). After 168 hours, the total amount of free vancomycin
in chambers A and B was 137.9 g and of ceftazidime, 127.2
g, compared with the respective initial levels of 125 and 275
g, suggesting no loss of vancomycin but a 54% decrease in
ceftazidime. At 48 hours, the concentration of free ceftazidime
in the dialysis chambers B was 73.4 g/mL (Fig. 1B).
In another experiment with the antibiotics prepared in BSS,
the vancomycin concentration in chamber B again increased to
slightly more than 50% of the original concentration in cham-
ber A after approximately 70 hours. For ceftazidime, after an
initial crossover into chamber B within the first 10 hours, there
was a decrease in concentration by more than 90% after 40
hours (Fig. 2A). At the end of 168 hours, the total amount of
free vancomycin in chambers A and B was 135.6 g and of
ceftazidime 34.5 g, against the respective initial additions of
125 g and 275 g, suggesting no loss of vancomycin but
approximately 88% loss of ceftazidime. At 48 hours, the con-
centration of free ceftazidime in dialysis chamber B was 6.3
g/mL (Fig. 2B).
DISCUSSION
In the clinical setting, the observation of ceftazidime precipi-
tates is infrequently reported.14 This may be related to a poor
view of the fundus in the presence of infective endophthalmi-
tis, with corneal edema, inflammatory debris, intraocular lens
opacities and/or vitreitis. The alkaline pH due to the presence
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TABLE 1. Checkerboard Study Showing the Change with Time in Concentrations of Ceftazidime and Vancomycin
in Normal Saline and Balanced Salt Solution
A. Initial concentrations
0/0 0/250 0/125 0/62.5 0/31.25
550/0 550/250 550/125 550/62.5 550/31.25
275/0 275/250 275/125 275/62.5 275/31.25
137.5/0 137.5/250 137.5/125 137.5/62.5 137.5/31.25
68.75/0 68.75/250 68.75/125 68.75/62.5 68.75/31.25
B. Concentrations in NS at 24 hours
0/0 0/280.4 0/142.6 0/68.23 0/36.37
432.91/0 398.73/241.2 434.81/122.9 444.3/64.98 374.05/34.22
222.15/0 225.95/272.7 222.15/129.5 224.05/66.28 235.44/35.66
121.52/0 119.62/264.1 105.53/132.2 110.13/65.67 117.72/36.01
56.96/0 53.16/271 56.96/139.7 62.66/65.47 64.56/35.04
C. Concentrations in NS at 48 hours
0/0 0/295.5 0/144 0/66.05 0/35.28
413.92/0 349.37/236.7 387.34/136.6 383.54/64.01 400.63/34.01
209.21/0 177.63/227.6 205.26/132.1 165.79/63.11 197.37/32.8
112.5/0 153.95/372 100.66/140.8 102.63/62.74 120.39/31.34
75/0 57.24/285.1 59.21/146.6 55.26/62.87 76.97/33.98
D. Percentage decrease in concentrations in NS at 24 hours
0/0 0/0* 0/0* 0/0* 0/0*
21.3/0 27.5/3.5 20.9/1.7 19.2/0* 32.0/0*
19.2/0 17.8/0* 19.2/0* 18.5/0* 14.4/0*
11.6/0 13.0/0* 25.4/0* 19.9/0* 14.4/0*
17.1/0 22.7/0* 17.8/0* 8.6/0* 6.0/0*
E. Percentage decrease in concentrations in NS at 48 hours
0/0 0/0* 0/0* 0/0* 0/0*
24.7/0 36.5/5.3 29.6/0* 30.3/0* 27.2/0*
23.9/0 35.4/9.0 25.4/0* 39.7/0* 28.2/0*
18.2/0 12.0/0* 26.8/0* 25.4/0* 12.4/0*
0/0* 16.7/0* 13.9/0* 19.6/0* 0/0*
F. Concentrations in BSS at 24 hours
0/0 0/238.1 0/111.1 0/52.84 0/29.39
64.47/0 76.97/223.9 75/106.2 74.34/52.93 74.34/29.46
30.92/0 34.21/223.3 35.53/101.1 32.89/52.26 30.92/28.73
14.28/0 17.11/227.5 16.45/110.8 16.05/52.98 17.37/29.69
8.29/0 9.21/232.5 8.82/119.6 10.13/52.17 9.21/29.39
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of sodium carbonate in the ceftazidime formulation may lead to
precipitation of the antibiotic.13 However, precipitation has
been reported in formulation free of sodium carbonate.9 In our
study, the pH of the vitreous did not change with the addition
of the two antibiotics, and it remained unchanged when cefta-
zidime precipitated. We also found ceftazidime precipitation to
be temperature dependent, occurring at 37°C but not at am-
bient temperature. Moreover, we showed that vancomycin did
not precipitate in NS, BSS, or vitreous. Ceftazidime precipitated
regardless of the presence of vancomycin, and it precipitated
more extensively if it was initially prepared in BSS rather than
NS, even though the volume was small, suggesting the effective
enhancing precipitation effects of mineral materials in the BSS.
Precipitation was faster when the ceftazidime preparation was
added to vitreous or BSS than to NS, most likely due to the
presence of potassium ions, calcium ions, glutathione, and
other reducing and oxidizing agents. In the presence of intra-
vitreal inflammatory debris and endotoxin in endophthalmitis,
the extent of precipitation may even be greater and faster,
which may account for the shorter half-life of ceftazidime in
inflamed eyes when compared with that in control eyes.16
During pars plana vitrectomy, BSS is more suitable for in-
travitreal irrigation than NS because it contains the appropriate
bicarbonate, pH, and ions necessary for the maintenance of
normal retinal electrical activity.17 It is also preferred over NS
for use in anterior segment surgery, because it contains gluta-
thione, which is necessary for maintenance of endothelial cell
adenosine triphosphatase and for protection against free radi-
cal damage and oxidative stress.18 However, in the current
study we showed that ceftazidime was much more prone to
precipitation in BSS than in NS. If ceftazidime has to be admin-
istered intravitreally for the treatment of endophthalmitis, NS
should be preferred over BSS to avoid formation of precipi-
tates. However, this is impossible when intravitreal antibiotics
were given at the end of pars plana vitrectomy, which is
routinely performed today with the continuous infusion of BSS.
We have shown that when ceftazidime was initially pre-
pared in BSS, 6.3 g/mL free drug remained at 48 hours in a
volume of vitreous humor of 4 mL approximating that of an
emmetropic eye. Such concentration is still higher than the
minimal inhibitory concentration at 50% (MIC50) of ceftazi-
dime against common Gram-negative bacteria commonly iden-
tified in our hospital (Table 2),19 but it is close to that of
Acinetobacter spp., Pseudomonas aeruginosa, and other
nonfermenters. In addition, it is lower than the 90% mini-
mal inhibitory concentration (MIC90) against Enterobacter,
Citrobacter, and Acinetobacter spp. and other nonfermenters.
When ceftazidime was initially prepared in NS before injection,
the extent of precipitation was less and the amount of free
ceftazidime available was approximately 73.4 g/mL at 48
hours. The resultant concentration should be higher, but still
less than the respective MIC90 of these organisms. Such con-
centrations would not be considered adequate to treat vision-
threatening infections. Moreover, the antibiotic concentration
may be even lower in large, myopic eyes with more vitreous
volume than normal, or in the presence of aphakia or pseu-
TABLE 1 (continued). Checkerboard Study Showing the Change with Time in Concentrations of Ceftazidime and Vancomycin
in Normal Saline and Balanced Salt Solution
G. Concentrations in BSS at 48 hours
0/0 0/222.8 0/82.2 0/50.58 0/27.56
22.84/0 23.21/206.6 22.29/114.3 25.24/48.83 22.29/26.58
13.82/0 13.03/233.0 13.24/110.4 13.16/49.58 13.42/27.3
7.11/0 7.5/226.8 7.37/88.9 7.24/50.44 7.11/27.73
4.34/0 3.68235.2 3.62/111.9 3.49/51.09 3.68/27.64
H. Percentage decrease in concentrations in BSS at 24 hours
0/0 0/4.5 0/11.1 0/15.4 0/6.0
88.3/0 86.0/10.4 86.4/15.0 86.5/15.3 86.5/5.73
94.3/0 87.6/10.7 87.0/19.1 88.0/16.4 88.8/8.1
89.6/0 87.6/9.0 88.0/11.3 88.3/15.2 87.4/5.0
87.9/0 86.8/7.0 87.2/4.3 85.3/16.5 86.6/6.0
I. Percentage decrease in concentrations in BSS at 48 hours
0/0 0/10.9 0/34.2 0/19.1 0/11.8
95.8/0 95.8/17.4 95.9/8.6 95.4/21.9 95.9/11.8
95.0/0 95.3/6.8 95.1/11.7 95.2/20.7 95.1/15.0
94.8/0 94.5/9.3 94.6/28.9 94.7/19.3 94.8/12.6
93.7/0 94.65.9 94.7/10.5 94.9/18.3 94.6/11.6
Each box in each section of the table signifies a well in a microtiter plate. To determine how the two antibiotics ceftazidine and vancomycin
interact at different concentrations, various amounts (in milligrams per liter) of ceftazidime and vancomycin were mixed in each well (A), with
normal saline or with balanced salt solution, and incubated at 37°C. The contents of each well were aliquoted after 24 h and 48 hours for assay
of concentration and percentage decrease in concentration of antibiotics. Data in sections (B), (C), (F), and (G) show the measurable
concentrations in milligrams per liter and in (D), (E), (H), and (I) the percentage decrease in concentrations of ceftazidime/vancomycin in the two
media at the 24- and 48-hour measurement time points.
* No measurable loss.
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dophakia which hastens the elimination of intravitreal drugs
such as ceftazidime.16 Nonetheless, the microbiologic spec-
trum and susceptibility of postoperative endophthalmitis are
different among the United States and European and Asian
countries.3,20,21 Resistance to ceftazidime among Gram-nega-
tive organisms up to 39% of cases has been reported in India.21
Our experimental findings, based on an equilibrium dialysis
system, may not be a perfect representation of what actually
happens during clinical treatment of endophthalmitis. We used
vitreous from cadaveric eyes, which have different solubility
parameters, such as pH and electrolyte concentrations, com-
pared with vitreous in infected eyes. The activities of metabolic
FIGURE 1. Equilibrium dialysis in vitreous medium with vancomycin and ceftazidime initially prepared in NS. Percentage (A) and actual (B)
changes in concentration are shown.
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enzymes were also different. Such discrepancies in experimen-
tal and physiological conditions pose a limitation in extrapo-
lating our in vitro collected data to in vivo clinical applications.
However, based on our and other available data,8,10,13,14 we
suggest that ceftazidime not be used as the first-line treatment
for infective endophthalmitis until further studies have vali-
dated its safety and efficacy. For the time being, the use of
amikacin, as recommended by the Endophthalmitis Vitrectomy
Study, is advisable.5
In summary, this in vitro study showed ceftazidime precip-
itation regardless of the presence of vancomycin at body tem-
perature. NS is preferable to BSS in preparing the antibiotics for
intravitreal injection in lessening the extent of ceftazidime
precipitation. However, the concentration of free ceftazidime
FIGURE 2. Equilibrium dialysis in vitreous medium with vancomycin and ceftazidime initially prepared in BSS. Percentage (A) and actual (B)
changes in concentration are shown.
IOVS, April 2002, Vol. 43, No. 4 Antibiotic Precipitation Study 1187
Downloaded from iovs.arvojournals.org on 06/29/2019
in vitreous may not be sufficiently high for antibacterial action
against most common organisms. We are looking into such
precipitation properties of other potent anti-Gram-negative an-
tibiotics with broad-spectrum antibacterial action including
fluoroquinolone and meropenem. Investigation of whether
precipitation affects the free concentrations of these antibiot-
ics and, possibly their efficacy and clinical usefulness, is in
progress using a similar experimental model.
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TABLE 2. Minimal Inhibitory Concentration of Ceftazidime against
Common Gram-Negative Bacteria Isolated from the
Bloodstream in a Teaching Hospital
Bacterial Species MIC50 MIC90
Escherichia coli 0.12 0.5
Klebsiella spp. 0.12 0.5
Indole-positive Proteus spp. 0.06 8
Proteus mirabilis 0.06 0.06
Enterobacter, Citrobacter 0.25 128
Acinetobacter spp. 4 128
Pseudomonas aeruginosa 1 4
Other nonfermenters 2 128
Data are expressed as micrograms per milliliter.
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